Building on our previous work that demonstrated the potential of BA-BNCT for treating radioresistant HCC [16], the present study introduces a novel radiosensitization strategy by combining BA-BNCT with RAD51 inhibition using B02. The gene discussed is RAD51; the disease is hepatocellular carcinoma.